|
211 |
VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke. |
VITATOPS Trial Study Group; Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Xavier D, et al. |
Int J Stroke |
2007 |
|
212 |
Glucose-insulin potassium therapy in patients with ST-segment elevation myocardial infarction. |
Díaz R, Goyal A, Xavier D, et al; |
JAMA. |
2007 |
|
213 |
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in stroke patients |
Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group. |
Cerebrovasc Dis |
2007 |
|
214 |
Perspectives on the management of coronary artery disease in India. |
Karthikeyan G, Xavier D, Prabhakaran D, Pais P. |
Heart |
2007 |
|
215 |
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. |
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, et al; |
JAMA |
2006 |
|
216 |
Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. |
Devereaux PJ, Yang H, Guyatt GH, Pais P, Xavier D, Yusuf S, et al. |
Am Heart J |
2006 |
|
217 |
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. |
Teo KK, Ounpuu S, Hawken S, Pandey MR, Yusuf S, et al; |
Lancet 2006 |
2006 |
|
218 |
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. |
MICHELANGELO OASIS 5 Steering Committee, Mehta SR, Yusuf S, et al; |
Am Heart J |
2005 |
|
219 |
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. |
Yusuf S, Hawken S, Ounpuu S, et al; |
Lancet. |
2005 |
|
220 |
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. |
Yusuf S, Mehta SR, Xavier D, Pais P, Zhu J, Liu L, et al; |
JAMA |
2005 |
|
221 |
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. |
Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al; |
JAMA |
2005 |
|
222 |
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. |
Yusuf S, Mehta SR, Pais P, Xavier D, et al; |
AmHeart J. |
2004 |
|
223 |
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study |
Yusuf S, Hawken S, Ounpuu S, Budaj A, Pais P, INTERHEART Study Investigators et al; |
Lancet |
2004 |
|
224 |
Risk factors for acute myocardial infarction in Indians: case-control study. |
Prem P, J Pogue , H Gerstein, Salim Yusuf, et al; |
Lancet |
1996 |